Why involve payers now?

During the draft protocol phase, involving payers helps translate strategic value ambitions into an executable study design. This stage is critical for embedding payer‑relevant evidence requirements directly into the protocol—before design elements are finalized—so the resulting data package can support real‑world decision‑making, reimbursement considerations, and market access objectives across target markets.

By addressing the following considerations, you can create a clinical protocol that is more likely to meet the needs of payers and support successful reimbursement and market access for the intervention.

1. Relevance of Outcomes: Ensure that the clinical outcomes measured are relevant to payer evidence needs. This includes not only clinical efficacy but also health economics outcomes such as cost-effectiveness, quality of life, and long-term benefits.
2. Patient Population: Clearly define the patient population and ensure it reflects the real-world population that payers are interested in. This includes considering comorbidities, age groups, and other demographic factors.
3. Comparator Selection: Choose appropriate comparators that are relevant to the current standard of care. Payers are interested in how the new intervention compares to existing treatments in terms of both efficacy and cost.
4. Study Design: Consider incorporating pragmatic design elements, where appropriate, to better reflect real-world clinical practice. This can include broader inclusion criteria and less stringent control over treatment administration.
5. Endpoints: Include both primary and secondary endpoints that are meaningful to payers. This might include endpoints related to healthcare utilization, such as hospitalizations, emergency room visits, and medication adherence.
6. Health Economics: Plan for health economic analyses into the protocol. This can include cost-effectiveness analysis, budget impact analysis, and other economic evaluations that demonstrate the value of the intervention.
7. Regulatory and Reimbursement Landscape: Understand the regulatory and reimbursement landscape across target markets, including payer evidence expectations for coverage.
8. Partner Engagement: Engage payers during protocol development to incorporate relevant evidence perspectives. This can help ensure that their perspectives and requirements are considered and can increase the likelihood of successful reimbursement.
9. Data Collection and Reporting: Plan for comprehensive data collection that includes not only clinical outcomes but also patient-reported outcomes and health resource utilization. Ensure that the data collected can be used to support payer submissions.
10. Real-World Evidence: Consider how real-world evidence (RWE) can be integrated into the protocol. RWE can provide additional insights into the effectiveness and value of the intervention in routine clinical practice.

Input at this stage helps ensure the protocol generates evidence that supports both regulatory approval and reimbursement decisions.